Regulatory B cells in anti-tumor immunity

International Immunology

Volumn 27, Issue 10, 2015, Pages 521-530

  Zhang, Yu ^a   Gallastegui, Nicolas ^a   Rosenblatt, Joseph D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tumor immunity; B regulatory cells; IL 10; TGF

Indexed keywords

CD40 ANTIGEN; INTERLEUKIN 10; OX40 LIGAND; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; IL10 PROTEIN, HUMAN;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CARCINOGENESIS; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; LYMPHATIC SYSTEM TUMOR; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN CARCINOGENESIS; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TH1 TH2 BALANCE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; AUTOIMMUNE DISEASE; CELL LINEAGE; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HODGKIN DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; NONHODGKIN LYMPHOMA; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES, REGULATORY; CELL LINEAGE; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; LYMPHOMA, NON-HODGKIN; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84946713832     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxv034     Document Type: Article

References (116)

1. Qin, Z., Richter, G., Schüler, T., Ibe, S., Cao, X. and Blankenstein, T. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4:627.
2. Shah, S., Divekar, A. A., Hilchey, S. P. et al. 2005. Increased rejection of primary tumors in mice lacking B cells: inhibition of antitumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 117:574.
3. Lee-Chang, C., Bodogai, M., Martin-Montalvo, A. et al. 2013. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J. Immunol. 191:4141.
4. Inoue, S., Leitner, W. W., Golding, B. and Scott, D. 2006. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 66:7741.
5. Fremd, C., Schuetz, F., Sohn, C., Beckhove, P. and Domschke, C. 2013. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2:e25443.
6. Gunderson, A. J. and Coussens, L. M. 2013. B cells and their mediators as targets for therapy in solid tumors. Exp. Cell Res. 319:1644.
7. Nelson, B. H. 2010. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185:4977.
8. Monach, P. A., Schreiber, H. and Rowley, D. A. 1993. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55:1356.
9. Brodt, P. and Gordon, J. 1978. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J. Immunol. 121:359.
10. de Visser, K. E., Korets, L. V. and Coussens, L. M. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411.
11. Schioppa, T., Moore, R., Thompson, R. G. et al. 2011. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc. Natl Acad. Sci. USA 108:10662.
12. Nzula, S., Going, J. J. and Stott, D. I. 2003. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 63:3275.
13. Kammertoens, T., Qin, Z., Briesemeister, D., Bendelac, A. and Blankenstein, T. 2012. B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin). Int. J. Cancer 131:1499.
14. Ammirante, M., Luo, J. L., Grivennikov, S., Nedospasov, S. and Karin, M. 2010. B-cell-derived lymphotoxin promotes castrationresistant prostate cancer. Nature 464:302.
15. Kobayashi, T., Hamaguchi, Y., Hasegawa, M., Fujimoto, M., Takehara, K. and Matsushita, T. 2014. B cells promote tumor immunity against B16F10 melanoma. Am. J. Pathol. 184:3120.
16. Forte, G., Sorrentino, R., Montinaro, A. et al. 2012. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J. Immunol. 189:2226.
17. Zhou, P., Qiu, J., L'Italien, L. et al. 2010. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J. Immunother. 33:789.
18. Cunningham-Rundles, C. 2011. Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin. Exp. Immunol. 164(Suppl. 2):6.
19. Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S. and Bhan, A. K. 2002. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16:219.
20. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. and Anderton, S. M. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3:944.
21. Carter, N. A., Rosser, E. C. and Mauri, C. 2012. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 14:R32.
22. Yanaba, K., Bouaziz, J. D., Haas, K. M., Poe, J. C., Fujimoto, M. and Tedder, T. F. 2008. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28:639.
23. Blair, P. A., Noreña, L. Y., Flores-Borja, F. et al. 2010. CD19(+) CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32:129.
24. Ding, Q., Yeung, M., Camirand, G. et al. 2011. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 121:3645.
25. Zhao, G., Moore, D. J., Lee, K. M. et al. 2010. An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Am. J. Transplant. 10:796.
26. Sträter, J., Mariani, S. M., Walczak, H. et al. 1999. CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L. Am. J. Pathol. 154:193.
27. Tinhofer, I., Marschitz, I., Kos, M. et al. 1998. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 91:4273.
28. Müllauer, L., Mosberger, I. and Chott, A. 1998. Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod. Pathol. 11:369.
29. Kondo, E., Yoshino, T., Nishiuchi, R. et al. 1997. Expression of Fas ligand mRNA in germinal centres of the human tonsil. J. Pathol. 183:75.
30. Minagawa, R., Okano, S., Tomita, Y. et al. 2004. The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen. Transplantation 78:799.
31. Hagn, M., Sontheimer, K., Dahlke, K. et al. 2012. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol. Cell Biol. 90:457.
32. Kaltenmeier, C., Gawanbacht, A., Beyer, T. et al. 2015. CD4+ T cell-derived IL-21 and deprivation of CD40 signaling favor the in vivo development of granzyme B-expressing regulatory B cells in HIV patients. J. Immunol. 194:3768.
33. Chesneau, M., Michel, L., Dugast, E.et al. 2015. Tolerant kidney transplant patients produce B cells with regulatory properties. J. Am. Soc. Nephrol. Published online February 2, 2015. doi:10.1681/ASN.2014040404.
34. Lee, K. M., Stott, R. T., Zhao, G. et al. 2014. TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur. J. Immunol. 44:1728.
35. Ray, A., Basu, S., Williams, C. B., Salzman, N. H. and Dittel, B. N. 2012. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J. Immunol. 188:3188.
36. Saze, Z., Schuler, P. J., Hong, C. S., Cheng, D., Jackson, E. K. and Whiteside, T. L. 2013. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 122:9.
37. Yang, C., Lee, H., Pal, S. et al. 2013. B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One 8:e64159.
38. Kortylewski, M. and Yu, H. 2007. Stat3 as a potential target for cancer immunotherapy. J. Immunother. 30:131.
39. Sattler, S., Ling, G. S., Xu, D. et al. 2014. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J. Autoimmun. 50:107.
40. Wang, R. X., Yu, C. R., Dambuza, I. M. et al. 2014. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20:633.
41. Rosser, E. C., Oleinika, K., Tonon, S. et al. 2014. Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production. Nat. Med. 20:1334.
42. Zhang, Y., Eliav, Y., Shin, S. U. et al. 2013. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol. Immunother. 62:87.
43. Lundy, S. K. 2009. Killer B lymphocytes: the evidence and the potential. Inflamm. Res. 58:345.
44. Lindner, S., Dahlke, K., Sontheimer, K. et al. 2013. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 73:2468.
45. Rafei, M., Hsieh, J., Zehntner, S. et al. 2009. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 15:1038.
46. Meiler, F., Zimmermann, M., Blaser, K., Akdis, C. A. and Akdis, M. 2006. T-cell subsets in the pathogenesis of human asthma. Curr. Allergy Asthma Rep. 6:91.
47. Akdis, M., Trautmann, A., Klunker, S. et al. 2003. T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J. 17:1026.
48. Nilsson, N., Ingvarsson, S. and Borrebaeck, C. A. 2000. Immature B cells in bone marrow express Fas/FasL. Scand. J. Immunol. 51:279.
49. Lundy, S. K., Berlin, A. A., Martens, T. F. and Lukacs, N. W. 2005. Deficiency of regulatory B cells increases allergic airway inflammation. Inflamm. Res. 54:514.
50. Nagafuchi, H., Wakisaka, S., Takeba, Y., Takeno, M., Sakane, T. and Suzuki, N. 2002. Aberrant expression of Fas ligand on anti-DNA autoantibody secreting B lymphocytes in patients with systemic lupus erythematosus: "immune privilege"-like state of the autoreactive B cells. Clin. Exp. Rheumatol. 20:625.
51. Hahne, M., Renno, T., Schroeter, M. et al. 1996. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26:721.
52. Gondek, D. C., Lu, L. F., Quezada, S. A., Sakaguchi, S. and Noelle, R. J. 2005. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174:1783.
53. Jahrsdörfer, B., Vollmer, A., Blackwell, S. E. et al. 2010. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115:1156.
54. Yoshizaki, A., Miyagaki, T., DiLillo, D. J. et al. 2012. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491:264.
55. Tadmor, T., Zhang, Y., Cho, H. M., Podack, E. R. and Rosenblatt J. D. 2011. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol. Immunother. 60:609.
56. Zhang, Y., Morgan, R., Podack, E. R. and Rosenblatt, J. 2013. B cell regulation of anti-tumor immune response. Immunol. Res. 57:115.
57. Perricone, M. A., Smith, K. A., Claussen, K. A. et al. 2004. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother. 27:273.
58. Oizumi, S., Deyev, V., Yamazaki, K. et al. 2008. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells. J. Immunother. 31:394.
59. Harris, D. P., Haynes, L., Sayles, P. C. et al. 2000. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1:475.
60. Kinoshita, T., Ishii, G., Hiraoka, N. et al. 2013. Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma. Cancer Sci. 104:409.
61. Heeren, A. M., Koster, B. D., Samuels, S. et al. 2015. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. Cancer Immunol. Res. 3:48.
62. Wei, B., Velazquez, P., Turovskaya, O. et al. 2005. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc. Natl Acad. Sci. USA 102:2010.
63. Olkhanud, P. B., Damdinsuren, B., Bodogai, M. et al. 2011. Tumorevoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res. 71:3505.
64. Yanaba, K., Bouaziz, J. D., Matsushita, T., Magro, C. M., St Clair, E. W. and Tedder, T. F. 2008. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223:284.
65. Iwata, Y., Matsushita, T., Horikawa, M. et al. 2011. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117:530.
66. Hsu, L. H., Li, K. P., Chu, K. H. and Chiang, B. L. 2015. A B-1a cell subset induces Foxp3(-) T cells with regulatory activity through an IL-10-independent pathway. Cell. Mol. Immunol. 12:354
67. Linton, P. J., Bautista, B., Biederman, E. et al. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197:875.
68. So, T., Song, J., Sugie, K., Altman, A. and Croft, M. 2006. Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment. Proc. Natl Acad. Sci. USA 103:3740.
69. Ishii, N., Ndhlovu, L. C., Murata, K., Sato, T., Kamanaka, M. and Sugamura, K. 2003. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses. Eur. J. Immunol. 33:2372.
70. Ohshima, Y., Yang, L. P., Uchiyama, T. et al. 1998. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 92:3338.
71. Wejksza, K., Lee-Chang, C., Bodogai, M. et al. 2013. Cancerproduced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor a. J. Immunol. 190:2575.
72. Han, S., Feng, S., Ren, M. et al. 2014. Glioma cell-derived placental growth factor induces regulatory B cells. Int. J. Biochem. Cell Biol. 57:63.
73. Andreu, P., Johansson, M., Affara, N. I. et al. 2010. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17:121.
74. Affara, N. I., Ruffell, B., Medler, T. R. et al. 2014. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25:809.
75. Burger, J. A., Ghia, P., Rosenwald, A. and Caligaris-Cappio, F. 2009. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114:3367.
76. Shain, K. H., Dalton, W. S. and Tao, J. 2015. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene. Advance online publication February 2, 2015; doi:10.1038/onc.2014.403.
77. Sander, B., de Jong, D., Rosenwald, A. et al. 2014. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica 99:715.
78. Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. and Ansell, S. M. 2006. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 66:10145.
79. Yang, Z. Z., Novak, A. J., Stenson, M. J., Witzig, T. E. and Ansell, S. M. 2006. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639.
80. Fischbach, W. 2014. Gastric MALT lymphoma-update on diagnosis and treatment. Best Pract. Res. Clin. Gastroenterol. 28:1069.
81. Arcaini, L., Merli, M., Volpetti, S., Rattotti, S., Gotti, M. and Zaja, F. 2012. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin. Dev. Immunol. 2012:638185.
82. Gu, Z., Cai, B., Yuan, L. et al. 2014. Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression. Int. J. Clin. Exp. Med. 7:1904.
83. Ansell, S. M. and Vonderheide, R. H. 2013. Cellular composition of the tumor microenvironment. Am. Soc. Clin. Oncol. Educ. Book. doi:10.1200/EdBook_AM.2013.33.e91. ISSN 1548-8756 (Electronic); 1548-8748 (Linking).
84. Wilcox, R. A., Wada, D. A., Ziesmer, S. C. et al. 2009. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114:2936.
85. Ansell, S. M. 2013. Malignant B cells at the helm in follicular lymphoma. J. Clin. Oncol. 31:2641.
86. Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. and Ansell, S. M. 2009. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 69:5522.
87. Yang, Z. Z., Grote, D. M., Ziesmer, S. C. et al. 2012. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 122:1271.
88. Yang, Z. Z., Grote, D. M., Ziesmer, S. C. et al. 2013. Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS One 8:e59456.
89. Yang, Z. Z., Grote, D. M., Xiu, B. et al. 2014. TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia 28:1872.
90. Juszczynski, P., Ouyang, J., Monti, S. et al. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl Acad. Sci. USA 104:13134.
91. Riley, J. L. 2009. PD-1 signaling in primary T cells. Immunol. Rev. 229:114.
92. Steidl, C., Telenius, A., Shah, S. P. et al. 2010. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116:418.
93. Green, M. R., Monti, S., Rodig, S. J. et al. 2010. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268.
94. Yamamoto, R., Nishikori, M., Kitawaki, T. et al. 2008. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111:3220.
95. Ansell, S. M., Lesokhin, A. M., Borrello, I. et al. 2015. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372:311.
96. Armand, P., Nagler, A., Weller, E. A. et al. 2013. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31:4199.
97. Westin, J. R., Chu, F., Zhang, M. et al. 2014. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, openlabel, phase 2 trial. Lancet Oncol. 15:69.
98. Carragher, D. M., Rangel-Moreno, J. and Randall, T. D. 2008. Ectopic lymphoid tissues and local immunity. Semin. Immunol. 20:26.
99. Drayton, D. L., Liao, S., Mounzer, R. H. and Ruddle, N. H. 2006. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7:344.
100. Tamiolakis, D., Simopoulos, C., Cheva, A. et al. 2002. Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Eur. J. Gynaecol. Oncol. 23:433.
101. Coronella, J. A., Spier, C., Welch, M. et al. 2002. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J. Immunol. 169:1829.
102. Yakirevich, E., Izhak, O. B., Rennert, G., Kovacs, Z. G. and Resnick, M. B. 1999. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod. Pathol. 12:1050.
103. Chin, Y., Janseens, J., Vandepitte, J., Vandenbrande, J., Opdebeek, L. and Raus, J. 1992. Phenotypic analysis of tumorinfiltrating lymphocytes from human breast cancer. Anticancer Res. 12:1463.
104. Germain, C., Gnjatic, S., Tamzalit, F. et al. 2014. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189:832.
105. Dieu-Nosjean, M. C., Antoine, M., Danel, C. et al. 2008. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26:4410.
106. Al-Shibli, K. I., Donnem, T., Al-Saad, S., Persson, M., Bremnes, R. M. and Busund, L. T. 2008. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 14:5220.
107. Riemann, D., Wenzel, K., Schulz, T. et al. 1997. Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. Int. Arch. Allergy Immunol. 114:38.
108. Nedergaard, B. S., Ladekarl, M., Nyengaard, J. R. and Nielsen, K. 2008. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol. Oncol. 108:106.
109. Milne, K., Köbel, M., Kalloger, S. E. et al. 2009. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4:e6412.
110. Reuschenbach, M., von Knebel Doeberitz, M. and Wentzensen, N. 2009. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother. 58:1535.
111. Yasuda, M., Mizukami, M., Hanagiri, T. et al. 2006. Antigens recognized by IgG derived from tumor-infiltrating B lymphocytes in human lung cancer. Anticancer Res. 26:3607.
112. Kotlan, B., Simsa, P., Teillaud, J. L. et al. 2005. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J. Immunol. 175:2278.
113. Kotlan, B., Simsa, P., Foldi, J. et al. 2003. Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma. Hum. Antibodies 12:113.
114. Nozoe, T., Yasuda, M., Honda, M., Inutsuka, S. and Korenaga, D. 2007. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. Hepatogastroenterology 54:1422.
115. Ichiki, Y., Takenoyama, M., Mizukami, M. et al. 2004. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J. Immunol. 172:4844.
116. Aklilu, M., Stadler, W. M., Markiewicz, M. et al. 2004. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann. Oncol. 15:1109.